Agenda

  • 14:50
    Online platform open for connecting participants
  • 15:00
    Welcome and introduction
  • 15:05
    Challenges with IP in Orpan drugs
  • 15:10
    Building an Orphan Oncology company: Past experience and future perspectives
  • 15:30
    Regulatory challenges in small populations
  • 15:50
    Patient identification and recruitment strategies in orphan oncology
  • 16:10
    Big pharma perspective/Danish Biotech
  • 16:20
    Discussion and Q&A
  • 16:30
    Event ends

    Online event invitation August 24th 2021- Development of Orphan Drugs within Oncology

    starts:24/08/2021 ends:24/08/2021 from:15:00 to:16:30 organizer: address:Online email: sn@mva.org www: Link >> Import to calendar

    Venue: Online

    Date: 24/08/2021

    Time: 15:00 - 16:30

    MVA ONCOLOGY NETWORK MEETING – DEVELOPMENT OF ORPHAN DRUGS WITHIN ONCOLOGY

    Medicon Valley Alliance together with Ascelia Pharma have the pleasure to invite DANSK BIOTEK members to the 11th meeting of the Medicon Valley Alliance Oncology Network on the 24th of August, 2021.

    In this MVA Oncology network webinar Ascelia Pharma will share knowledge on how they are building an international biotech company focusing on Orphan Oncology. You will also hear from leading regulatory experts from NDA Advisory Board and get insights from TFS Health Services on Patient recruitment and patient identification in orphan oncology.

    Due to the current Covid-19 situation in Denmark and Sweden this meeting is delivered in a shorter webinar format instead of a regular networking meeting.

    Register here no later than August 23rd 2021. You can read more about the event and speakers using the link above.

    If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

    Copyright 2021 Danskbiotek. All rights reserved.